Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature
Standard
Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature. / Reher, Dominik; Schramm, Christoph; Brinkert, Florian; Weidemann, Sören Alexander; Plauth, Mathias; Lohse, Ansgar Wilhelm; Weiler-Normann, Christina.
in: GastroHep, Jahrgang 1, Nr. 1, 19.11.2018, S. 33-44.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature
AU - Reher, Dominik
AU - Schramm, Christoph
AU - Brinkert, Florian
AU - Weidemann, Sören Alexander
AU - Plauth, Mathias
AU - Lohse, Ansgar Wilhelm
AU - Weiler-Normann, Christina
PY - 2018/11/19
Y1 - 2018/11/19
N2 - Background: Eosinophilic cholangitis (EC) is a rare inflammatory disorder leading tobiliary obstruction. Diagnosis is challenging since EC can mimic malignant disease.No standardised treatment is available so far. Aim of this case series was the analy-sis of symptoms, diagnostic and therapeutic outcomes in EC patients.Methods: A systematic research of the available scientific literature was performedusing PubMed. Search keywords that were used included “eosinophilic cholangitis, ”“eosinophilic cholangiopathy,”“eosinophilic infiltration” and “biliary obstruction.” Fiveadditional cases of EC treated at University Medical Center Hamburg‐Eppendorfwere analysed.Results: Forty cases of EC were included in the analysis. Most frequent clinicalsymptoms were abdominal pain (70%) and jaundice (48%). Laboratory evaluationrevealed abnormal liver function tests (100%) and peripheral eosinophilia (82%).Treatment consisted of immunosuppression (18 patients [45%]), surgery (12 patients[30%]) or a combination of both (nine patients [23%]). In 17 patients who were trea-ted without immunosuppression or in whom immunosuppression was withdrawn,clinical condition or laboratory tests deteriorated.Conclusions: Immunosuppression is an effective therapy in the majority of patientssuffering from EC. In case of advanced hepatic damage or disease recurrence, long‐term immunosuppression should be considered. Histology and interdisciplinarycollaboration is essential for diagnosis and management of EC
AB - Background: Eosinophilic cholangitis (EC) is a rare inflammatory disorder leading tobiliary obstruction. Diagnosis is challenging since EC can mimic malignant disease.No standardised treatment is available so far. Aim of this case series was the analy-sis of symptoms, diagnostic and therapeutic outcomes in EC patients.Methods: A systematic research of the available scientific literature was performedusing PubMed. Search keywords that were used included “eosinophilic cholangitis, ”“eosinophilic cholangiopathy,”“eosinophilic infiltration” and “biliary obstruction.” Fiveadditional cases of EC treated at University Medical Center Hamburg‐Eppendorfwere analysed.Results: Forty cases of EC were included in the analysis. Most frequent clinicalsymptoms were abdominal pain (70%) and jaundice (48%). Laboratory evaluationrevealed abnormal liver function tests (100%) and peripheral eosinophilia (82%).Treatment consisted of immunosuppression (18 patients [45%]), surgery (12 patients[30%]) or a combination of both (nine patients [23%]). In 17 patients who were trea-ted without immunosuppression or in whom immunosuppression was withdrawn,clinical condition or laboratory tests deteriorated.Conclusions: Immunosuppression is an effective therapy in the majority of patientssuffering from EC. In case of advanced hepatic damage or disease recurrence, long‐term immunosuppression should be considered. Histology and interdisciplinarycollaboration is essential for diagnosis and management of EC
U2 - https://doi.org/10.1002/ygh2.209
DO - https://doi.org/10.1002/ygh2.209
M3 - SCORING: Journal article
VL - 1
SP - 33
EP - 44
JO - GastroHep
JF - GastroHep
SN - 1478-1239
IS - 1
ER -